| Trial ID: | L7197 |
| Source ID: | NCT02933853
|
| Associated Drug: |
Faster-Acting Insulin Aspart
|
| Title: |
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Faster-acting insulin aspart|DRUG: Insulin Aspart
|
| Outcome Measures: |
Primary: Area under the serum insulin aspart concentration-time curve, From 0 to 30 minutes | Secondary: Maximum observed serum insulin aspart concentration, Within 0 to 12 hours after dosing|Area under the glucose infusion rate curve, From 0 to t, where t is the last time where glucose infusion rate (GIR) exceeds zero (within 0 to 12 hours after dosing)|Maximum glucose infusion rate, Within 0 to 12 hours after dosing
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
61
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2016-10-14
|
| Completion Date: |
2017-12-21
|
| Results First Posted: |
|
| Last Update Posted: |
2019-05-24
|
| Locations: |
Novo Nordisk Investigational Site, Graz, 8010, Austria
|
| URL: |
https://clinicaltrials.gov/show/NCT02933853
|
